drugset / Trial / NCT01011283
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the response of patients with Intermediate or High Risk myelodysplastic syndromes (MDS) following treatment with decitabine or azacitidine.
Timeline
- Start
- 2009-11
- Primary completion
- 2011-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Comparator | Decitabine | Small molecule | 20 mg/m2 | Intravenous |